• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于肠道微生物群的宏基因组特征用于非侵入性检测人类非酒精性脂肪性肝病中的晚期纤维化

Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

作者信息

Loomba Rohit, Seguritan Victor, Li Weizhong, Long Tao, Klitgord Niels, Bhatt Archana, Dulai Parambir Singh, Caussy Cyrielle, Bettencourt Richele, Highlander Sarah K, Jones Marcus B, Sirlin Claude B, Schnabl Bernd, Brinkac Lauren, Schork Nicholas, Chen Chi-Hua, Brenner David A, Biggs William, Yooseph Shibu, Venter J Craig, Nelson Karen E

机构信息

NAFLD Research Center, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

Human Longevity, San Diego, CA 92121, USA.

出版信息

Cell Metab. 2017 May 2;25(5):1054-1062.e5. doi: 10.1016/j.cmet.2017.04.001.

DOI:10.1016/j.cmet.2017.04.001
PMID:28467925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5502730/
Abstract

The presence of advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is the most important predictor of liver mortality. There are limited data on the diagnostic accuracy of gut microbiota-derived signature for predicting the presence of advanced fibrosis. In this prospective study, we characterized the gut microbiome compositions using whole-genome shotgun sequencing of DNA extracted from stool samples. This study included 86 uniquely well-characterized patients with biopsy-proven NAFLD, of which 72 had mild/moderate (stage 0-2 fibrosis) NAFLD, and 14 had advanced fibrosis (stage 3 or 4 fibrosis). We identified a set of 40 features (p < 0.006), which included 37 bacterial species that were used to construct a Random Forest classifier model to distinguish mild/moderate NAFLD from advanced fibrosis. The model had a robust diagnostic accuracy (AUC 0.936) for detecting advanced fibrosis. This study provides preliminary evidence for a fecal-microbiome-derived metagenomic signature to detect advanced fibrosis in NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)中晚期纤维化的存在是肝脏死亡率的最重要预测指标。关于肠道微生物群衍生特征预测晚期纤维化存在的诊断准确性的数据有限。在这项前瞻性研究中,我们使用从粪便样本中提取的DNA进行全基因组鸟枪法测序来表征肠道微生物组组成。本研究纳入了86例经活检证实为NAFLD且特征明确的患者,其中72例患有轻度/中度(0-2期纤维化)NAFLD,14例患有晚期纤维化(3期或4期纤维化)。我们鉴定出一组40个特征(p < 0.006),其中包括37种细菌,用于构建随机森林分类器模型,以区分轻度/中度NAFLD和晚期纤维化。该模型在检测晚期纤维化方面具有强大的诊断准确性(AUC 0.936)。本研究为粪便微生物组衍生的宏基因组特征检测NAFLD中的晚期纤维化提供了初步证据。

相似文献

1
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.基于肠道微生物群的宏基因组特征用于非侵入性检测人类非酒精性脂肪性肝病中的晚期纤维化
Cell Metab. 2017 May 2;25(5):1054-1062.e5. doi: 10.1016/j.cmet.2017.04.001.
2
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.非酒精性脂肪性肝病相关肝硬化的肠道微生物组特征。
Nat Commun. 2019 Mar 29;10(1):1406. doi: 10.1038/s41467-019-09455-9.
3
Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.与儿童非酒精性脂肪性肝病患者的脂肪性肝炎和中重度纤维化相关的微生物组特征。
Gastroenterology. 2019 Oct;157(4):1109-1122. doi: 10.1053/j.gastro.2019.06.028. Epub 2019 Jun 27.
4
A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic Liver Disease Mainly Due to NAFLD.一种微生物特征可识别主要由非酒精性脂肪性肝病引起的慢性肝病患者的晚期纤维化。
Sci Rep. 2020 Feb 17;10(1):2771. doi: 10.1038/s41598-020-59535-w.
5
A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.一种通用的肠道微生物组衍生特征可预测肝硬化。
Cell Metab. 2020 Nov 3;32(5):878-888.e6. doi: 10.1016/j.cmet.2020.06.005. Epub 2020 Jun 30.
6
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.肠道病毒组特征与非酒精性脂肪性肝病严重程度相关。
Gastroenterology. 2020 Nov;159(5):1839-1852. doi: 10.1053/j.gastro.2020.07.005. Epub 2020 Jul 9.
7
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.非酒精性脂肪性肝病的严重程度与肠道菌群失调及肠道微生物群代谢功能的改变有关。
Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13.
8
Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.肠道微生物衍生代谢物与非酒精性脂肪性肝病肝脂肪变性和纤维化的共享基因效应之间的关系。
Hepatology. 2018 Sep;68(3):918-932. doi: 10.1002/hep.29892. Epub 2018 May 20.
9
Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation.单核细胞-巨噬细胞激活与 HIV 单核感染相关的非酒精性脂肪性肝病和肝纤维化有关,而与肠道微生物组和细菌易位无关。
AIDS. 2019 Apr 1;33(5):805-814. doi: 10.1097/QAD.0000000000002133.
10
Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.非肥胖型非酒精性脂肪性肝病患者中与显著肝纤维化相关的肠道微生物组和代谢物的独特特征。
Nat Commun. 2020 Oct 5;11(1):4982. doi: 10.1038/s41467-020-18754-5.

引用本文的文献

1
Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies.探索代谢功能障碍相关脂肪性肝病与肠道菌群失调之间的相互作用:病理生理学、临床意义及新兴疗法。
World J Hepatol. 2025 Aug 27;17(8):108730. doi: 10.4254/wjh.v17.i8.108730.
2
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病(MASLD):肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
3

本文引用的文献

1
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.非酒精性脂肪性肝病中纤维化阶段导致的死亡风险增加:系统评价与荟萃分析
Hepatology. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31.
2
Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.通过测量组织和血液中的细胞外基质重塑率来识别患有活动性纤维化的非酒精性脂肪性肝病患者。
Hepatology. 2017 Jan;65(1):78-88. doi: 10.1002/hep.28860. Epub 2016 Nov 15.
3
Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis.
Helicobacter hepaticus promotes hepatic steatosis through CdtB-induced mitochondrial stress and lipid metabolism reprogramming.
肝螺杆菌通过CdtB诱导的线粒体应激和脂质代谢重编程促进肝脂肪变性。
Nat Commun. 2025 Aug 26;16(1):7954. doi: 10.1038/s41467-025-63351-z.
4
Hepatitis and periodontal health: an emerging oral-liver axis.肝炎与牙周健康:一个新兴的口腔-肝脏轴
Ther Adv Chronic Dis. 2025 Aug 20;16:20406223251368090. doi: 10.1177/20406223251368090. eCollection 2025.
5
The role of microbiota in nonalcoholic fatty liver disease: mechanism of action and treatment strategy.微生物群在非酒精性脂肪性肝病中的作用:作用机制与治疗策略。
Front Microbiol. 2025 Jul 30;16:1621583. doi: 10.3389/fmicb.2025.1621583. eCollection 2025.
6
Influence of Matcha and Tea Catechins on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-A Review of Patient Trials and Animal Studies.抹茶和茶儿茶素对代谢功能障碍相关脂肪性肝病(MASLD)进展的影响——患者试验和动物研究综述
Nutrients. 2025 Jul 31;17(15):2532. doi: 10.3390/nu17152532.
7
Credible inferences in microbiome research: ensuring rigour, reproducibility and relevance in the era of AI.微生物组研究中的可靠推断:在人工智能时代确保严谨性、可重复性和相关性
Nat Rev Gastroenterol Hepatol. 2025 Jul 31. doi: 10.1038/s41575-025-01100-9.
8
Deep Learning Transforms Phage-Host Interaction Discovery from Metagenomic Data.深度学习改变了从宏基因组数据中发现噬菌体-宿主相互作用的方式。
bioRxiv. 2025 Jun 27:2025.05.26.656232. doi: 10.1101/2025.05.26.656232.
9
Constructing inflammatory bowel disease diagnostic models based on k-mer and machine learning.基于k-mer和机器学习构建炎症性肠病诊断模型
Front Microbiol. 2025 Jun 25;16:1578005. doi: 10.3389/fmicb.2025.1578005. eCollection 2025.
10
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma.代谢功能障碍相关脂肪性肝病及相关肝细胞癌中的肠道微生物群
Nat Rev Gastroenterol Hepatol. 2025 Jul 7. doi: 10.1038/s41575-025-01089-1.
肥胖患者肝纤维化相关血液微生物群特征的变化:一项初步分析。
Hepatology. 2016 Dec;64(6):2015-2027. doi: 10.1002/hep.28829.
4
Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis.胆固醇7α-羟化酶通过维持胆固醇稳态来保护肝脏免受炎症和纤维化的影响。
J Lipid Res. 2016 Oct;57(10):1831-1844. doi: 10.1194/jlr.M069807. Epub 2016 Aug 17.
5
Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study.肝脂肪变性与肝纤维化之间的共同遗传效应:一项前瞻性双生子研究。
Hepatology. 2016 Nov;64(5):1547-1558. doi: 10.1002/hep.28674. Epub 2016 Jul 25.
6
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.磁共振成像(MRI)和磁共振弹性成像(MRE)用于非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)中肝脂肪变性和纤维化的无创定量评估:从临床试验到临床实践
J Hepatol. 2016 Nov;65(5):1006-1016. doi: 10.1016/j.jhep.2016.06.005. Epub 2016 Jun 14.
7
Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge.抑制高迁移率族蛋白B1的易位和细胞外释放可减轻纤维化小鼠在D-半乳糖胺/脂多糖攻击下的肝损伤。
Mol Med Rep. 2016 May;13(5):3835-41. doi: 10.3892/mmr.2016.5003. Epub 2016 Mar 18.
8
Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?肠道微生物群的变化与酒精性和非酒精性肝病:是原因还是结果?
Gastroenterology. 2016 Jun;150(8):1745-1755.e3. doi: 10.1053/j.gastro.2016.02.073. Epub 2016 Mar 4.
9
Targeting Dysbiosis for the Treatment of Liver Disease.针对肠道菌群失调治疗肝脏疾病
Semin Liver Dis. 2016 Feb;36(1):37-47. doi: 10.1055/s-0035-1571276. Epub 2016 Feb 12.
10
Confounding Effects of Metformin on the Human Gut Microbiome in Type 2 Diabetes.二甲双胍对 2 型糖尿病患者肠道微生物组的混杂影响。
Cell Metab. 2016 Jan 12;23(1):10-2. doi: 10.1016/j.cmet.2015.12.012.